Premix Vancomycin Injection in Sodium Chloride Launched

Baxter International Inc has launched a ready-to-use version of Vancomycin injection.

Baxter International Inc has launched a ready-to-use version of Vancomycin injection.

The product, which treats infections caused by susceptible strains of methicillin-resistant staphylococci, comes in 0.9% sodium chloride in 500 mg, 750 mg, and 1 gram presentations.

“As a company whose mission is focused on saving and sustaining lives, Baxter’s launch of Vancomycin injection as an innovative premixed saline presentation provides new options of an important antibiotic to address patient needs and demonstrates our commitment to making premixed preparations of medications more efficient for health care practitioners,” said Brik Eyre, president of Baxter’s Hospital Products business, in a press release.

Baxter is currently the only manufacturer to offer the antibiotic in a premixed presentation.

The launch of this product is an extension of Baxter’s existing line of Vancomycin injection in 5% dextrose (available in 500 mg, 750 mg and 1 gram presentations). The new alternative can be useful for patients who may need to avoid additional dextrose.

Baxter’s premix technology is designed for unstable molecules that are often administered using standard doses.